Pfizer (PFE) announced results from the Phase 3 TALAPRO-2 study of TALZENNA, an oral poly ADP-ribose polymerase inhibitor, in combination with ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Revenue from COVID vaccine Comirnaty brought in sales of $3.38 billion, while antiviral treatment Paxlovid was $727 million ...

US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, moved closer to securing the top health job on ...

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax, following in the footsteps of Pfizer/BioNTech, which filed their Comirnaty shot ...

Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis ...

Moderna Inc. MRNA edged up 0.58%, while Pfizer Inc. PFE gained 2.95% amid heightened focus on potential bird flu preparedness. CDC official John Nkengasong‘s Sunday memo, viewed by The ...

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking system and its counterpart on the station. Thanks to international ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...

Recently, Pfizer found itself in the agency's crosshairs thanks to one of its M&A plays. Now, Pfizer—which purchased neuroscience specialist Biohaven for $11.6 billion in 2022—is committing ...